Hoatlin Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(133 intermediate revisions by 6 users not shown)
Line 1: Line 1:
=Welcome to the Hoatlin Lab Wiki in development=
{{HoatlinLab}}


Our lab is interested in understanding how the [http://www.fanconi.org/ Fanconi anemia] proteins contribute to genomic stability with the goal of developing drugs that will help Fanconi patients and those who are susceptible to developing cancer.
<div style="padding: 15px; width: 710px; border: 5px solid #B3CD4E;">
We work in [http://www.pova.org/ Portland, Oregon] at [http://www.ohsu.edu/ OHSU], in the [http://www.ohsu.edu/biochem/ Department of Biochemistry & Molecular Biology]. Our Departmental web pages (not updated wiki-frequently) can be viewed [http://www.ohsu.edu/research/hoatlin/ here (web page)] and [http://www.ohsu.edu/biochem/faculty/faculty.cfm?facultyID=29 here (faculty page)].
<div style="padding: 1px; width: 700px; border: 3px solid #DDDDFF;">


We hope that other Fanconi labs will join us at [http://openwetware.org/wiki/ OpenWetWare] because it might stimulate collaborative efforts, facilitate reagent distribution, and expand communication. We also believe that an understanding of the complex and enigmatic Fanconi anemia protein network could benefit from the attention of systems/synthetic biologists already on OWW.  
<div style="border:1px solid orange;background-color:#FFFACD;padding:1px;">
----
'''Lab News'''
;For news, follow the [http://twitter.com/HoatlinLab Hoatlin lab Twitter]
</div>
<br>
Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility. The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility.  Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer.  


[[Image:Labphoto.jpg|right|frame|[[Hoatlin:Research Team|Research Team]]]]
We work in [[Hoatlin:Portland Oregon| Portland, Oregon]] at [http://www.ohsu.edu/ OHSU], in the [http://www.ohsu.edu/biochem/ Department of Biochemistry & Molecular Biology] and the [http://www.ohsucancer.com/ OHSU Knight Cancer Institute].
*[[Hoatlin:Research Interests|Research Interests]]
*[[Hoatlin:Research Team|Research Team]]
*[[Hoatlin:Publications|Publications]]
*[[Hoatlin:Projects|Projects]]
*[[Hoatlin:Collaborations|Collaborations]]
*[[Hoatlin:Reagent Requests|Reagent Requests]]
*[[Hoatlin:Protocols|Standard Protocols]]
*[[Hoatlin:Internal Lab Site|Internal Lab Site]]
*[[Hoatlin: View from our Lab|Our View]]
*[[Hoatlin:Photos That Never Get Old|Photo Extravaganza]]
*[[Hoatlin:Contribute|Contribute to FA Research]]
*[[Hoatlin:Courses and Curriculum Development|Courses and Curriculum Development]]
*[[Hoatlin:News|Hoatlin Lab News]]
*[[Hoatlin:Contact Info|Contact Info & Directions]]
==[[Hoatlin:OHSU Replication, Recombination and Repair (R3) Club|OHSU DNA Replication, Recombination and Repair (R3) Club]]==


[[Image:Hoatlin_lab_logo.png|thumb|left|frame|"Frog Eggs Rule" illustration by Sobeck&Hoatlin]]
==Bio for Maureen Hoatlin==


[[Simple_wiki_editing_examples|wiki edit instructions]]
Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU).  After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers.  She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002.  Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway.  Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds.
 
Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development.
 
==Teaching Links==
 
*Our lab's Fanconi Anemia antibodies are available from [http://www.novusbio.com Novus Biologicals] and by Millipore.
 
[http://openwetware.org/wiki/CANB_610 Advanced Topics in Cancer Biology (CANB 610)]
 
[[Hoatlin:OHSU_Genetic_Mechanisms_Class| Genetic Mechanisms Class (CON662)]]
 
[[Hoatlin:OHSU Replication, Recombination and Repair (R3) Club| OHSU DNA Replication, Recombination and Repair (R3) Club]].
 
[[Hoatlin: CSF|Med Students Fundamentals]]
 
==Biochemistry Seminar Series==
[http://openwetware.org/wiki/Hoatlin:BMB_seminar_series_'15-'16 Biochemistry Seminar Series Working Draft]
 
==Classes of the past==
[[BMCB625|Advanced Topics in Molecular Biology(BMB625)]]
 
==Who is Visiting Us?==
 
'''Who's visiting?'''
 
<html>
<a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Hoatlin_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Hoatlin_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'">
</a>
</html>
[[Image:Hoatlinclustermap.jpg]]
 
==Basic Wiki/OWW Links==
 
*[http://openwetware.org/wiki/Help:Contents Help Overview]
 
*[[OpenWetWare:How_to_join | How to join]]
 
*[[OWW.101:OpenWetWare | Using OpenWetWare]]
 
*[[OWW.101:Guidelines for editing OpenWetWare|Guidelines for editing OpenWetWare]]
 
<wikionly>
<font size=4>'''Recent changes'''</font>{{Special:Recentchanges/Hoatlin}}
</wikionly>

Revision as of 10:56, 18 August 2016

Equipped with his five senses, man explores the universe around him and calls the adventure Science. ~Edwin Powell Hubble, The Nature of Science, 1954

Home        Projects        Team        Papers        Contact Us        Protocols        Collaborations        News        Reagent Requests        secret back door        Hoatlin Lab Twitter       



Lab News

For news, follow the Hoatlin lab Twitter


Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility. The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility. Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer.

We work in Portland, Oregon at OHSU, in the Department of Biochemistry & Molecular Biology and the OHSU Knight Cancer Institute.

Bio for Maureen Hoatlin

Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU). After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers. She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002. Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway. Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds.

Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development.

Teaching Links

  • Our lab's Fanconi Anemia antibodies are available from Novus Biologicals and by Millipore.

Advanced Topics in Cancer Biology (CANB 610)

Genetic Mechanisms Class (CON662)

OHSU DNA Replication, Recombination and Repair (R3) Club.

Med Students Fundamentals

Biochemistry Seminar Series

Biochemistry Seminar Series Working Draft

Classes of the past

Advanced Topics in Molecular Biology(BMB625)

Who is Visiting Us?

Who's visiting?

<html> <a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Hoatlin_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Hoatlin_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'"> </a> </html>

Basic Wiki/OWW Links

<wikionly>

Recent changes
List of abbreviations:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes

16 April 2024

15 April 2024

     23:43  User:Yanbin Huang‎‎ 2 changes history +170 [Yanbin Huang‎ (2×)]
     
23:43 (cur | prev) 0 Yanbin Huang talk contribs (→‎Granted Patents)
     
23:43 (cur | prev) +170 Yanbin Huang talk contribs (→‎Granted Patents)
     22:11  The paper that launched microfluidics - Xi Ning‎‎ 14 changes history +9,705 [Xning098‎ (14×)]
     
22:11 (cur | prev) −6 Xning098 talk contribs (→‎Summary)
     
22:07 (cur | prev) −12 Xning098 talk contribs (→‎Synthesis)
     
22:06 (cur | prev) 0 Xning098 talk contribs
     
22:06 (cur | prev) +1 Xning098 talk contribs
     
22:05 (cur | prev) 0 Xning098 talk contribs
     
22:03 (cur | prev) +630 Xning098 talk contribs
     
22:01 (cur | prev) +3,189 Xning098 talk contribs
     
21:44 (cur | prev) +688 Xning098 talk contribs (→‎Separation and quantification)
     
21:33 (cur | prev) +306 Xning098 talk contribs
     
21:29 (cur | prev) −2 Xning098 talk contribs (→‎Electrokinetic effect)
     
21:28 (cur | prev) −1 Xning098 talk contribs (→‎Separation and quantification)
     
21:27 (cur | prev) +398 Xning098 talk contribs (→‎Separation and quantification)
     
21:24 (cur | prev) +2,812 Xning098 talk contribs
     
21:06 (cur | prev) +1,702 Xning098 talk contribs
     21:45  (Upload log) [Xning098‎ (4×)]
     
21:45 Xning098 talk contribs uploaded File:Figure 4 Tdesign.png
     
21:30 Xning098 talk contribs uploaded File:Figure 3 Set-up3.png
     
21:24 Xning098 talk contribs uploaded File:Figure 2 Set-up1.png
     
21:09 Xning098 talk contribs uploaded File:Figure 1 electroosmotic flow.png
N    18:16  Multilayer Paper Microfluidics - Madyson Redder‎‎ 21 changes history +6,228 [Mredder‎ (21×)]
     
18:16 (cur | prev) +540 Mredder talk contribs (→‎Fabrication Methods)
     
18:07 (cur | prev) +822 Mredder talk contribs (→‎Fabrication Methods)
     
17:58 (cur | prev) +1,223 Mredder talk contribs (→‎Fabrication Methods)
     
17:47 (cur | prev) −47 Mredder talk contribs (→‎Motivation for Multilayer Paperfluidics)
     
17:46 (cur | prev) +2 Mredder talk contribs (→‎Advantages)
     
17:46 (cur | prev) +1,094 Mredder talk contribs (→‎Advantages)
     
17:37 (cur | prev) +24 Mredder talk contribs (→‎Materials)
     
17:37 (cur | prev) +619 Mredder talk contribs (→‎Materials)
     
17:19 (cur | prev) +18 Mredder talk contribs (→‎Uses)
     
17:19 (cur | prev) +7 Mredder talk contribs (→‎Uses)
     
17:18 (cur | prev) −19 Mredder talk contribs (→‎Developing Countries and Travel)
     
17:18 (cur | prev) +15 Mredder talk contribs (→‎Uses)
     
17:16 (cur | prev) 0 Mredder talk contribs (→‎Uses)
     
17:16 (cur | prev) +1,103 Mredder talk contribs (→‎Uses)
     
17:14 (cur | prev) −453 Mredder talk contribs (→‎Motivation for Multilayer Paperfluidics)
     
17:13 (cur | prev) +1 Mredder talk contribs (→‎Overview)
     
17:12 (cur | prev) +273 Mredder talk contribs (→‎Overview)
     
17:08 (cur | prev) −699 Mredder talk contribs (→‎Overview)
     
17:06 (cur | prev) +95 Mredder talk contribs
     
17:04 (cur | prev) +12 Mredder talk contribs
N    
17:03 (cur | prev) +1,598 Mredder talk contribs (Created page with "{{Template:CHEM-ENG590E}} Overview 3D polymeric or glass microfluidic devices were created to run tests on small amounts of liquid and receive results in a timely manner. However, these devices are costly and time consuming to produce. A solution to this problem was single-layer paper microfluidic devices. The most common known examples of single-layer paper microfluidic devices are pregnancy tests, COVID-19 antigen tests, and glucose test strips. While these devices a...")
     17:02  CHEM-ENG590E:Wiki Textbook diffhist +54 Mredder talk contribs (→‎Chapter 7 - Fiber-based Microfluidics)
 m   07:22  Paper Microfluidic Device for Archiving Breast Epithelial Cells diffhist +6 Sarah L. Perry talk contribs
     06:39  Hu diffhist +66 Hugangqing talk contribs

14 April 2024

</wikionly>